Population Pharmacokinetics and Exposure-Response Analyses of Savolitinib Alone or in Combination With Osimertinib in Patients With Locally Advanced or Metastatic Solid Tumors.
Clin Transl SciSep 1, 2026
Azar Shahraz, Thibaud Derippe, Kiran Kumar Kode et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II clinical trial analyzed the population pharmacokinetics of savolitinib in 998 patients with advanced solid tumors. The study found a positive trend between savolitinib's steady-state trough concentration and objective response rates, particularly in the overall population, but not in patients with high MET biomarker status. No significant safety concerns were linked to savolitinib exposure.
Key findings
- A positive trend was observed between savolitinib Cmin,ss and objective response rate in the all-comer population.
- No clear trend was found in patients with high MET biomarker status.
- No statistically significant associations were identified between savolitinib exposure and most safety events.
Why it matters
Understanding the pharmacokinetics and exposure-response relationship of savolitinib can inform dosing strategies and enhance treatment efficacy in patients with advanced solid tumors, particularly when combined with osimertinib.